NCT07514104Completed
Extracorporeal Shock Wave Therapy in Enhancing Sensitivity and Postural Stability in Multiple Sclerosis
Efficacy of Extracorporeal Shock Wave Therapy in Enhancing Plantar Sensitivity and Postural Stability in Multiple Sclerosis: A Quantitative Gait and Sensory Analysis
Source: ClinicalTrials.gov · Last updated 7 Apr 2026
Brief summary (registry, in English)
This randomized controlled trial aimed to investigate the efficacy of Extracorporeal Shock Wave Therapy (ESWT) on plantar somatosensory function, knee joint proprioception, and spatiotemporal gait parameters in individuals diagnosed with Multiple Sclerosis (MS). The study included participants with a spasticity level below 1+, with the intervention group receiving ESWT three times per week over a 6-week period. To evaluate sensory changes, light touch thresholds were measured at six plantar sites-the heel, medial longitudinal arch, 1st and 5th metatarsal heads, and the 1st and 5th toes-using the Semmes-Weinstein monofilament kit. Additionally, two-point discrimination was assessed at the heel, and vibration duration was measured at the metatarsal heads using a 128 Hz tuning fork. Proprioception was quantified via the active knee joint reposition test in a closed kinetic chain position, measuring the absolute angular error at a 60° target angle. Postural stability and dynamic gait were objectively analyzed using the Win-Track platform and a reliable 3-step protocol to record parameters such as gait cycle duration, step length, cadence, and maximum plantar pressure. Static balance was further evaluated by recording the percentage of body weight transferred to each foot. By targeting both mechanoreceptor sensitivity and joint position sense, this 6-week ESWT intervention seeks to enhance the overall functional mobility and stability of MS patients.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 54 (actual)
- First submitted
- 30 Mar 2026
- Start date
- 1 Jul 2021
- Primary completion date
- 15 Feb 2025
- Lead sponsor
- Furkan Bilek
- Diseases
- Multiple sclerosis
- NCT number
- NCT07514104
What you commit to
- Study type: Interventional
- Participants enrolled: 54
- From 1 Jul 2021 to the primary completion date, 15 Feb 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Contraindications for Extracorporeal Shock Wave Therapy
Other illness
- Presence of severe cognitive impairment that prevents following test instructions
- Other neurological disorders (e.g., Parkinson's disease, polyneuropathy) that could interfere with sensory or gait assessments
- Presence of open wounds, active infections, or skin integrity issues on the plantar surface of the feet
Who the study is looking for
- Diagnosis of Multiple Sclerosis
- Spasticity level below 1+ according to the Modified Ashworth Scale
- Ability to walk independently or with assistive devices to perform the 3-step gait protocol
- Willingness to participate in a 6-week intervention involving bilateral plantar ESWT
- Stable medical condition without a recent relapse within the last 3 months
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fırat university Coordinator of this site? Confirm its status | Elâzığ | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.